Portugal

Mounjaro. EMA assesses alert on risk of vision loss

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 13/11/2026, 16:01:24 UTC.

Briefings

The European Medicines Agency (EMA) issued a warning regarding the risk of vision loss associated with injectable diabetes medications, following FDA alerts. This update concerns specific drug classes used for diabetes treatment and weight loss, highlighting regulatory changes in the pharmaceutical sector.

Key points

• The EMA issued a warning about the risk of vision loss for injectable diabetes medications following FDA alerts.
• Regulatory changes affect specific drug classes used for diabetes treatment and weight loss.

Context

The European Medicines Agency (EMA) issued a warning about the risk of vision loss for injectable diabetes medications following FDA alerts. This update concerns specific drug classes used for diabetes treatment and weight loss.

Limitations

The evidence is limited to a single sentence stating the EMA issued a warning. No specific drug names, dates of the warning, or quantitative data on vision loss rates are provided.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/11/2026, 08:38:55 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifelqeutei2jjlfo55pudfks452brklzl6ds3fshfn3jhswp6jxvm